Please visit the following to learn more about these clinical trials.
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
Read about the Ovarian Cancer Low Risk Study.
A Phase 1b/2 Study of Demcizumab plus Paclitaxel in Subjects with Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
POSITION: A PilOt Study of InducTion PARP InhibitiON in ovarian cancer
A Randomized Phase II Induction Discontinuation Trial of Emactuzumab following Paclitaxel and Bevacizumab in Patients with platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer
A Phase 1b Study of Navicixizumab (OMP-305B83) plus Weekly Paclitaxel in Subjects with Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors with Ras Pathway Alterations, and Ovarian Tumors with PARP Resistance